Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
J Hosp Med ; 11(3): 185-92, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26505618

ABSTRACT

BACKGROUND: Hospital evidence-based practice centers (EPCs) synthesize and disseminate evidence locally, but their impact on institutional decision making is unclear. OBJECTIVE: To assess the evidence synthesis activities and impact of a hospital EPC serving a large academic healthcare system. DESIGN, SETTING, AND PARTICIPANTS: Descriptive analysis of the EPC's database of rapid systematic reviews since EPC inception (July 2006-June 2014), and survey of report requestors from the EPC's last 4 fiscal years. MEASUREMENTS: Descriptive analyses examined requestor and report characteristics; questionnaire examined report usability, impact, and requestor satisfaction (higher scores on 5-point Likert scales reflected greater agreement). RESULTS: The EPC completed 249 evidence reviews since inception. The most common requestors were clinical departments (29%, n = 72), chief medical officers (19%, n = 47), and purchasing committees (14%, n = 35). The most common technologies reviewed were drugs (24%, n = 60), devices (19%, n = 48), and care processes (12%, n = 31). Mean report completion time was 70 days. Thirty reports (12%) informed computerized decision support interventions. More than half of reports (56%, n = 139) were completed in the last 4 fiscal years for 65 requestors. Of the 64 eligible participants, 46 responded (72%). Requestors were satisfied with the report (mean = 4.4), and agreed it was delivered promptly (mean = 4.4), answered the questions posed (mean = 4.3), and informed their final decision (mean = 4.1). CONCLUSIONS: This is the first examination of evidence synthesis activities by a hospital EPC in the United States. Our findings suggest hospital EPCs can efficiently synthesize and disseminate evidence addressing a range of clinical topics for diverse stakeholders, and can influence local decision making.


Subject(s)
Decision Making, Organizational , Evidence-Based Practice/methods , Hospital Administration , Information Dissemination/methods , Humans , Research Report , Surveys and Questionnaires , United States
2.
Acad Med ; 90(4): 450-3, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25426739

ABSTRACT

PROBLEM: Inpatient rotations remain a central component in residency training, particularly in specialties such as internal medicine. However, maintaining the quality of this important learning experience has become a challenge. Recent approaches to redesigning the inpatient rounding experience have included reductions in the number of admissions and in patient census, which may not be feasible or desirable for many programs. APPROACH: The authors designed and implemented an approach to inpatient teaching that maintained the standard patient volume. It had the following five goals: (1) enhance bedside clinical skills, (2) promote a culture of patient safety, (3) emphasize diagnostic reasoning, (4) engage patients, and (5) provide learners with an expanded perspective on patients' experiences of care. This redesign, called the Chiefs' Service (CS) program, was implemented in 2013. The CS team acted as the intervention group in a quasi-experimental design study evaluating and comparing their experiences and outcomes with those of the standard inpatient medical teams not using the CS model. OUTCOMES: Five key team activities, or elements, were developed, piloted, and refined with learner, attending, and patient feedback. Those elements were morning huddle, bedside rounds, diagnostic "time-outs," day-of-discharge rounds, and postdischarge follow-up rounds. NEXT STEPS: A robust evaluation process is under way; initial impressions from attendings, learners, and patients have been positive. Several educational outcomes also are being measured and compared with those of the standard inpatient medical teams. Further evaluations will guide modifications to the CS program and direct plans for dissemination within the institution and to other institutions.


Subject(s)
Inpatients , Internship and Residency/methods , Teaching Rounds/methods , Follow-Up Studies , Patient Discharge/standards , Safety
3.
J Hosp Med ; 9(9): 598-603, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24961204

ABSTRACT

Hospitals devote significant human and capital resources to eliminate hospital readmissions, prompted most recently by the Centers for Medicare and Medicaid Services (CMS) financial penalties for higher-than-expected readmission rates. Implicit in these efforts are assumptions that a significant proportion of readmissions are preventable, and preventable readmissions can be identified. Yet, no consensus exists in the literature regarding methods to determine which readmissions are reasonably preventable. In this article, we examine strengths and limitations of the CMS readmission metric, explore how preventable readmissions have been defined and measured, and discuss implications for readmission reduction efforts. Drawing on our clinical, research and operational experiences, we offer suggestions to address the key challenges in moving forward to measure and reduce preventable readmissions.


Subject(s)
Centers for Medicare and Medicaid Services, U.S. , Outcome Assessment, Health Care/methods , Patient Readmission , Humans , United States
5.
Int J Technol Assess Health Care ; 27(2): 127-32, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21450127

ABSTRACT

OBJECTIVES: Health systems frequently make decisions regarding acquisition and use of new technologies. It is desirable to base these decisions on clinical evidence, but often these technologies are used for multiple indications and evidence of effectiveness for one indication does not prove effectiveness for all. Here, we describe two examples of evidence inventory reports that were performed for the purposes of identifying how much and what type of published clinical evidence was available for a given technology, and the contexts in which those technologies were studied. METHODS: The evidence inventory reports included literature searches for systematic reviews and health technology assessment (HTA) reports, and systematic searches of the primary literature intended to count and categorize published clinical studies. The reports did not include analysis of the primary literature. RESULTS: The inventory reports were completed in 3 to 4 days each and were approximately ten pages in length, including references. Reports included tables listing the number of reported studies by specific indication for use, and whether or not there were randomized trials. Reports also summarized findings of existing systematic reviews and HTA reports, when available. Committees used the inventory reports to decide for which indications they wanted a full HTA report. CONCLUSIONS: Evidence inventory reports are a form of rapid HTA that can give decision makers a timely understanding of the available evidence upon which they can base a decision. They can help HTA providers focus subsequent reports on topics that will have the most influence on healthcare decision making.


Subject(s)
Decision Making , Evidence-Based Practice/methods , Health Planning/methods , Health Services , Technology Assessment, Biomedical/methods , Dexmedetomidine , Humans , Organizational Case Studies , Robotics , Surgery, Computer-Assisted
6.
Infect Control Hosp Epidemiol ; 32(2): 101-14, 2011 Feb.
Article in English | MEDLINE | ID: mdl-21460463

ABSTRACT

OBJECTIVE: To estimate the proportion of healthcare-associated infections (HAIs) in US hospitals that are "reasonably preventable," along with their related mortality and costs. METHODS: To estimate preventability of catheter-associated bloodstream infections (CABSIs), catheter-associated urinary tract infections (CAUTIs), surgical site infections (SSIs), and ventilator-associated pneumonia (VAP), we used a federally sponsored systematic review of interventions to reduce HAIs. Ranges of preventability included the lowest and highest risk reductions reported by US studies of "moderate" to "good" quality published in the last 10 years. We used the most recently published national data to determine the annual incidence of HAIs and associated mortality. To estimate incremental cost of HAIs, we performed a systematic review, which included costs from studies in general US patient populations. To calculate ranges for the annual number of preventable infections and deaths and annual costs, we multiplied our infection, mortality, and cost figures with our ranges of preventability for each HAI. RESULTS: As many as 65%-70% of cases of CABSI and CAUTI and 55% of cases of VAP and SSI may be preventable with current evidence-based strategies. CAUTI may be the most preventable HAI. CABSI has the highest number of preventable deaths, followed by VAP. CABSI also has the highest cost impact; costs due to preventable cases of VAP, CAUTI, and SSI are likely less. CONCLUSIONS: Our findings suggest that 100% prevention of HAIs may not be attainable with current evidence-based prevention strategies; however, comprehensive implementation of such strategies could prevent hundreds of thousands of HAIs and save tens of thousands of lives and billions of dollars.


Subject(s)
Catheter-Related Infections , Catheters/adverse effects , Cross Infection , Equipment Contamination , Catheter-Related Infections/economics , Catheter-Related Infections/epidemiology , Catheter-Related Infections/prevention & control , Catheters/microbiology , Costs and Cost Analysis , Cross Infection/economics , Cross Infection/epidemiology , Cross Infection/mortality , Cross Infection/prevention & control , Equipment Contamination/economics , Equipment Contamination/prevention & control , Health Care Surveys , Humans , Infection Control/methods , Pneumonia, Ventilator-Associated/economics , Pneumonia, Ventilator-Associated/epidemiology , Pneumonia, Ventilator-Associated/prevention & control , Regression Analysis , Risk Assessment , Sepsis/economics , Sepsis/etiology , Sepsis/prevention & control , Surgical Wound Infection/economics , Surgical Wound Infection/epidemiology , Surgical Wound Infection/etiology , Surgical Wound Infection/prevention & control , United States/epidemiology , Urinary Tract Infections/economics , Urinary Tract Infections/epidemiology , Urinary Tract Infections/etiology , Urinary Tract Infections/prevention & control
7.
J Gen Intern Med ; 25(12): 1352-5, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20697961

ABSTRACT

Hospital-based comparative effectiveness (CE) centers provide a model that clinical leaders can use to improve evidence-based practice locally. The model is used by integrated health systems outside the US, but is less recognized in the US. Such centers can identify and adapt national evidence-based policies for the local setting, create local evidence-based policies in the absence of national policies, and implement evidence into practice through health information technology (HIT) and quality initiatives. Given the increasing availability of CE evidence and incentives to meaningfully use HIT, the relevance of this model to US practitioners is increasing. This is especially true in the context of healthcare reform, which will likely reduce reimbursements for care deemed unnecessary by published evidence or guidelines. There are challenges to operating hospital-based CE centers, but many of these challenges can be overcome using solutions developed by those currently leading such centers. In conclusion, these centers have the potential to improve the quality, safety and value of care locally, ultimately translating into higher quality and more cost-effective care nationally. To better understand this potential, the current activity and impact of hospital-based CE centers in the US should be rigorously examined.


Subject(s)
Comparative Effectiveness Research/trends , Hospitals/trends , Patient Care/trends , Quality of Health Care/trends , Safety Management/trends , Translational Research, Biomedical/trends , Comparative Effectiveness Research/standards , Hospitals/standards , Humans , Patient Care/methods , Patient Care/standards , Quality of Health Care/standards , Safety , Safety Management/standards , Translational Research, Biomedical/methods , United States
8.
Int J Technol Assess Health Care ; 26(3): 294-300, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20584358

ABSTRACT

OBJECTIVES: Health technology assessment (HTA) programs influence practice on a broad scale through reimbursement decisions or national guidelines. Hospital-based HTA programs inform clinical decisions at the local level. Typically, they do this by adapting general HTA to their local setting, or by creating new HTA. However, unlike payer-based HTA organizations, hospital-based HTA organizations can also integrate local data into their reports. METHODS: We describe two examples of local data integrated into hospital-based HTA. In the first, qualitative data were used to select a new cardiac catheterization lab. In the second, quantitative data was used to inform a decision on whether to continue telemedicine services to critical care units. Local evidence sources included equipment service records, and interviews with physicians, technicians, and administrative staff in the first example, and the hospital's administrative and claims databases in the second example. RESULTS: In each case, there was little evidence from the peer-reviewed literature that could be applied to the decision. In the first example, staffing patterns and local preferences had considerable bearing on technology choices. In the second example, local outcomes data from administrative records were decisive. CONCLUSIONS: Hospital-based HTA using local data can fill gaps in the published evidence, and also improve the generalizability of evidence to the local setting. To take advantage of local evidence, health systems should encourage the development of hospital-based HTA centers, seek out local preference data, and maintain databases of patient outcomes and utilization of services.


Subject(s)
Hospital Administration , Information Management , Technology Assessment, Biomedical/organization & administration , Academic Medical Centers , Coronary Angiography , Organizational Case Studies , Pennsylvania , Purchasing, Hospital , Telemedicine
9.
J Neurosurg Spine ; 11(6): 729-40, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19951027

ABSTRACT

OBJECT: Autograft and allograft, the standard approaches for lumbar fusion procedures, have important disadvantages. Bone graft substitutes such as recombinant human bone morphogenetic proteins (rhBMP-2 and rhBMP-7) have emerged as viable alternatives. The authors conducted a systematic review to compare the efficacy and safety of osteoinductive bone graft substitutes using autografts and allografts in lumbar fusion. METHODS: A search for prospective controlled trials was conducted on MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials databases. Data were extracted for key outcomes including radiographically demonstrated nonunion, Oswestry Disability Index, operating time, blood loss, and length of hospital stay. The quality of randomized controlled trials was assessed using the Jadad scale. Meta-analyses were performed when feasible, and heterogeneity was assessed using the Q statistic and the I(2) statistic. RESULTS: Seventeen of 732 potential studies met the inclusion criteria, with 9 examining rhBMP-2, 3 examining rhBMP-7, 3 examining demineralized bone matrix, and 2 examining autologous growth factor. Recombinant human BMP-2 significantly decreased radiographic nonunion when compared with autologous iliac crest bone graft (AIBG) in a meta-analysis (relative risk 0.27, 95% CI 0.16-0.46). Stratification of meta-analyses by the type of surgical procedure performed yielded similar results. Funnel plots suggested publication bias. Trials of rhBMP-2 suggested reductions in the operating time and surgical blood loss, with less effect on the length of hospital stay. There was no difference in radiographic nonunion with the use of rhBMP-7 when compared with AIBG (relative risk 1.02, 95% CI 0.52-1.98). Neither rhBMP-2 nor rhBMP-7 demonstrated a significant improvement on the Oswestry Disability Index when compared with AIBG. The limited data on demineralized bone matrix and autologous growth factor showed no significant improvement in radiographic outcomes. CONCLUSIONS: Recombinant human BMP-2 may be an effective alternative to AIBG in lumbar fusion. Data are limited for other bone graft substitutes.


Subject(s)
Bone Morphogenetic Proteins/therapeutic use , Bone Substitutes/therapeutic use , Lumbar Vertebrae/surgery , Spinal Fusion/instrumentation , Humans , Osteogenesis/physiology
10.
Nephrol Dial Transplant ; 24(3): 856-63, 2009 Mar.
Article in English | MEDLINE | ID: mdl-18952698

ABSTRACT

BACKGROUND: In the past decade, more than 200 cases of nephrogenic systemic fibrosis (NSF) have been identified, primarily among patients with advanced kidney disease. Multiple studies have suggested an association between gadolinium-based contrast agents (GBCAs) and NSF. We performed a systematic review and meta-analysis to examine this potential association. METHODS: A systematic review of studies examining the association between any GBCA and NSF was performed. A search for controlled studies was conducted in MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. If controlled data for a GBCA was not available, we searched for case reports and series. Relevant data were extracted and meta-analyses were performed. RESULTS: Seven of 144 identified studies met inclusion criteria; gadodiamide was the sole or predominant GBCA in four of these; one study exclusively examined gadopentetate. Other GBCAs were not specifically examined in controlled or uncontrolled studies. Meta-analysis of controlled trials demonstrated a significant association between GBCA exposure and NSF [odds ratio (OR) 26.7; 95% confidence interval (CI) 10.3-69.4] and gadodiamide and NSF (OR 20.0; 95% CI 3.7-107.8). Examination of the evidence using established criteria suggested that this association was causal. CONCLUSIONS: The current state of evidence suggests an association and potentially causal link between the use of GBCAs and the development of NSF among patients with advanced kidney disease. Additional study is warranted to clarify the potential association of GBCAs other than gadodiamide with NSF.


Subject(s)
Contrast Media/adverse effects , Gadolinium/adverse effects , Kidney Diseases/complications , Nephrogenic Fibrosing Dermopathy/chemically induced , Organometallic Compounds/adverse effects , Humans , Kidney Diseases/therapy , Renal Dialysis
11.
J Adv Nurs ; 65(10): 2007-21, 2009 Oct.
Article in English | MEDLINE | ID: mdl-20568318

ABSTRACT

AIM: This paper is a report of a review to assess clinical studies comparing the effectiveness of different means of maintaining central venous catheter patency. BACKGROUND: Flushing with heparin is a routine part of central venous catheter maintenance, but it presents risks, including heparin-induced thrombocytopenia. Other techniques used to prevent occlusion of catheters include saline flushes, heparin-bonded catheters and pressure caps. DATA SOURCES: A search was conducted using the MEDLINE, CINAHL, EMBASE, Cochrane, National Guideline Clearinghouse and University Healthsystem Consortium databases. METHODS: A systematic review of effectiveness was conducted, using GRADE criteria to assess the strength of evidence for each intervention. The review period covered 1982 or earlier to January 2008. RESULTS: There is weak evidence that heparin flushing reduces occlusion of catheters, but no evidence that it reduces bloodstream infections. Results from clinical trials of pressure caps are inconsistent regarding their ability to maintain catheter patency, but provide moderate evidence that at least some varieties of caps are associated with increased bloodstream infections. CONCLUSION: The evidence base on heparin flushing and other interventions to prevent catheter occlusion is small, and published studies are of low quality. There is insufficient evidence on which to conclude that flushing catheters with heparin is more effective than flushing with saline solution.


Subject(s)
Anticoagulants/administration & dosage , Catheter-Related Infections/prevention & control , Catheterization, Central Venous/instrumentation , Heparin/administration & dosage , Infusions, Intra-Arterial , Adult , Anticoagulants/adverse effects , Catheter-Related Infections/etiology , Child , Child, Preschool , Equipment Failure , Evidence-Based Practice , Heparin/adverse effects , Humans , Infant , Infusions, Intra-Arterial/instrumentation , Nursing Research/methods , Practice Guidelines as Topic , Sodium Chloride/administration & dosage , Thrombocytopenia/chemically induced , Thrombosis/prevention & control , Treatment Outcome , Urokinase-Type Plasminogen Activator/administration & dosage
12.
Curr Opin Hematol ; 14(5): 455-67, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17934352

ABSTRACT

PURPOSE OF REVIEW: Antifibrinolytics are used to attenuate the coagulopathy associated with cardiopulmonary bypass. However, recent studies suggest that the antifibrinolytic aprotinin is associated with increased renal and vascular events and death compared to its alternatives. To develop a recommendation for antifibrinolytic use in adult cardiac surgery, we performed a systematic review and meta-analysis to determine the association of the antifibrinolytics with efficacy, safety and cost outcomes. RECENT FINDINGS: Aprotinin, when compared to placebo, significantly decreased blood transfusions and reoperations for bleeding, strokes and cognitive dysfunction, and significantly increased renal dysfunction but not renal failure. Tranexamic acid significantly decreased blood transfusions, but was not statistically associated with other outcomes. Aminocaproic acid was not statistically associated with any measured outcome. Although aprotinin costs more than its alternatives, its costs may approximate those of its alternatives when longer time horizons are considered. SUMMARY: We support the targeted use of aprotinin in adult cardiac surgery patients at high risk for bleeding or stroke, and discourage the use of aprotinin in those at high risk for renal failure. Although fewer data are available for tranexamic and aminocaproic acid, we support their use as alternatives to aprotinin in those at high risk for bleeding.


Subject(s)
Antifibrinolytic Agents/administration & dosage , Cardiac Surgical Procedures , Hemorrhage/prevention & control , Renal Insufficiency/prevention & control , Stroke/prevention & control , Adult , Antifibrinolytic Agents/economics , Cardiac Surgical Procedures/economics , Cardiopulmonary Bypass/economics , Hemorrhage/economics , Humans , Renal Insufficiency/economics , Stroke/economics
SELECTION OF CITATIONS
SEARCH DETAIL
...